AAOpt 2024: Qlosi's effectiveness in treatment of presbyopia
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent study that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
NIH announces definition of elements of brain-based visual impairment in children
Additional research is needed to establish best diagnostic and management strategies for increasingly common condition.
myze launches The Daily Lid Wipe, created with input from eye care professionals
The lid wipe contains tea tree oil, hyaluronic acid, and other antibacterial and antimicrobial ingredients like euphrasia, chamomile, and rhamnose
AAOpt 2024: The vision and comfort performance of Infuse multifocal contact lenses
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
AAOpt 2024: Key takeaways from the 2024 diabetes update
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
AAOpt 2024: Keeping contact lens wearers comfortable with Miebo
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
AAOpt 2024: The power of clinical insights
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
AAOpt 2024: Racial and socioeconomic disparities in diabetic eye disease
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting.
The white cane and beyond: Part 2
Navigation and orientation technologies offer practical solution for people with vision loss.
AAOpt 2024: Current concepts in pachychoroid spectrum diseases
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Base in(clusivity): A new type of prism in optometry school
With younger generations prompting a rise in individuals self-identifying as LGBTQ, schools and colleges of optometry should consider inclusivity as an integral part of education.
Alcon introduces expanded parameters for TOTAL30 for Astigmatism contact lens
The lens is now available in a -2.75D cylinder offering, according to a news release.
AAOpt 2024: Genetics and the cornea
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
IAPB announces winners of “Glasses of the Future” competition
Lama Albadeen, 8, of Saudi Arabia, and Grace Retta, 5, of Kenya, will receive cash prizes for their schools.
Study: Long-term blood pressure variability and visual field progression in glaucoma
A retrospective cohort study was designed to provide further information on the association between BP parameters and VF progression over time.
Finding the right fit as an LGBTQIA OD
Sometimes it takes several tries before settling into an inclusive practice that’s right for you.
AAOpt 2024: Honing in on epigenetics
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Aldeyra Therapeutics announced NDA acceptance for reproxalap for dry eye, expansion of exclusive option agreement
The dry eye drug has been assigned a PDUFA decision date of April 2, 2025, and the Aldeyra has chosen to expand their exclusive option agreement with AbbVie.
AAOpt 2024: Lotilaner's effectiveness in the treatment of Demodex blepharitis
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
US FDA issues Complete Response Letter for avacincaptad pegol (IZERVAY)
The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.